Effective obesity interventions could help more than 1.2 million adults in the UAE to overcome obesity, potentially contributing $51 billion to GDP by 2031, said a new report.
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.
Bahrain's National Health Regulatory Authority (NHRA) has approved Wegovy (semaglutide) pills, an oral GLP-1 treatment for obesity, in the kingdom. With this, Bahrain has become the second GCC country, after the UAE, and the fifth country worldwide to make the medicine available to its citizens.
